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A B S T R A C T
Purpose
For the past 65 years, patient age at diagnosis has beenwidely used as amajormortality risk factor in
the risk stratiﬁcation of papillary thyroid cancer (PTC), but whether this is generally applicable,
particularly in patients with different BRAF genetic backgrounds, is unclear. The current study was
designed to test whether patient age at diagnosis is a major mortality risk factor.
Patients and Methods
We conducted a comparative study of the relationship between patient age at diagnosis and PTC-
speciﬁc mortality with respect to BRAF status in 2,638 patients (623 men and 2,015 women) with
a median age of 46 years (interquartile range, 35 to 58 years) at diagnosis and a median follow-up
time of 58months (interquartile range, 26 to 107months). Elevenmedical centers from six countries
participated in this study.
Results
There was a linear association between patient age and mortality in patients with BRAF V600E
mutation, but not in patients with wild-type BRAF, in whom the mortality rate remained low and ﬂat
with increasing age. Kaplan-Meier survival curves rapidly declined with increasing age in patients
with BRAF V600E mutation but did not decline in patients with wild-type BRAF, even beyond age
75 years. The association betweenmortality and age in patients with BRAF V600Ewas independent
of clinicopathologic risk factors. Similar results were observed when only patients with the con-
ventional variant of PTC were analyzed.
Conclusion
The long-observed age-associated mortality risk in PTC is dependent on BRAF status; age is
a strong, continuous, and independent mortality risk factor in patients with BRAF V600E mutation
but not in patients with wild-type BRAF. These results question the conventional general use of
patient age as a high-risk factor in PTC and call for differentiation between patients with BRAF V600E
and wild-type BRAF when applying age to risk stratiﬁcation and management of PTC.
J Clin Oncol 36:438-445. © 2017 by American Society of Clinical Oncology
INTRODUCTION
Thyroid cancer is a common endocrine ma-
lignancy, and its incidence has rapidly increased
in recent decades.1-4 The most common histologic
type is papillary thyroid cancer (PTC), accounting
for . 85% of all thyroid malignancies, with con-
ventional PTC (CPTC) being the dominant variant.5,6
Risk stratiﬁcation is a critical component of standard
management of thyroid cancer and is currently based
mainly on clinicopathologic risk factors, among
which patient age at diagnosis is a major factor.
In 1953, Crile and Hazard7 described in detail
the association between advanced patient age and
unfavorable prognosis of thyroid cancer. Since then,
numerous studies have conﬁrmed this relationship.
Thus, patient age has long been routinely applied
as a major risk factor in risk stratiﬁcation of thyroid
cancer, which has profoundly impacted clinical prac-
tice in the management of thyroid cancer.8-10
The most important prognostic signiﬁcance
of patient age in thyroid cancer is its effect on
patient mortality; older patient age is strongly as-
sociated with thyroid cancer–speciﬁcmortality.11,12 In
fact, thyroid cancer is the only type of cancer for
which patient age is a metric for disease staging in the
American Joint Committee on Cancer (AJCC) and
Author afﬁliations and support information
(if applicable) appear at the end of this
article.
Published at jco.org on December 14,
2017.
X.S., G.Z., and R.L. contributed equally to
this work.
Corresponding author: Michael Mingzhao
Xing, MD, PhD, Division of Endocrinology,
Diabetes and Metabolism, The Johns
Hopkins University School of Medicine,
1830 EMonument St, Ste 333, Baltimore,
MD 21207; e-mail: mxing1@jhmi.edu.
© 2017 by American Society of Clinical
Oncology
0732-183X/18/3605w-438w/$20.00
ASSOCIATED CONTENT
See accompanying Editorial
on page 433
Appendix
DOI: https://doi.org/10.1200/JCO.
2017.74.5497
DOI: https://doi.org/10.1200/JCO.2017.
74.5497
438 © 2017 by American Society of Clinical Oncology
VOLUME 36 • NUMBER 5 • FEBRUARY 10, 2018
several other staging systems, reﬂecting the unique importance of
patient age as a risk factor in thyroid cancer. The age of 45 years has
been conventionally treated as a cutoff point demarcating the age-
associated risk in thyroid cancer13; however, this has been recently
changed to 55 years in the revised eighth edition of AJCC.14 Yet,
some studies have suggested that the mortality risk of thyroid cancer
continuously increases as patient age increases.15-18 A recent analysis
by Adam et al19 of 31,802 patients with PTC in the SEER database
demonstrated that age was associated with PTC-speciﬁc mortality in
a continuous linear manner without an age cutoff point. However,
critical questions remain unanswered as to why older patient age has
such a remarkable adverse effect on PTC-speciﬁc mortality and whether
age is a risk factor universally applicable to all patients with PTC.
The BRAF V600E mutation has been well known to be a main
oncogenic driver of PTC, occurring in approximately 45% of
patients.20-22 Many studies have demonstrated an association
between BRAF V600E and older patient age as well as poor clinical
outcomes, including recurrence of PTC23,24 and PTC-speciﬁc
mortality.25,26 Given these data, we hypothesized that BRAF
V600E might play an important role in the effect of patient age on
PTC-speciﬁc mortality, and that, in the absence of BRAF V600E,
patient age might not be a risk factor. We conducted this multi-
center study to test this hypothesis.
PATIENTS AND METHODS
Study Medical Centers, Countries, and Patients
With the approval of the institutional review boards of the partici-
pating institutions and, where required, informed written patient consent,
data from 2,638 patients with PTC on clinicopathologic characteristics and
PTC-speciﬁc patient death were collected from 11 medical centers in six
countries (Appendix Table A1, online only). These patients included 623
men (23.6%) and 2,015 women (76.4%) and had a median age of 46 years
(interquartile range, 35 to 58 years) at diagnosis of PTC and a median clinical
follow-up time of 58 months (interquartile range, 26 to 107 months) after the
initial surgery.BRAF genetic testing failed in 20 patients, whereas 1,524 patients
had wild-type BRAF and 1,094 patients had BRAF V600E mutation. Mortality
analysis was focused on PTC-speciﬁc patient death, as previously de-
ﬁned (ie, death that occurred as a result of incurable PTC disease that
invaded and compromised vital organs, causing the patient to die).25
Patient clinicopathologic characteristics that are well-known risk factors
for PTC-speciﬁc mortality are listed in Table 1. For a separate analysis of
patients with CPTC, a subset of 1,893 patients with CPTC was identiﬁed,
and exclusion of 14 patients without BRAF information left 996 and 883
patients who had wild-type BRAF and BRAF V600E. All of these patients
were consecutively selected and were treated with total or near-total thyroid-
ectomy for PTC; other treatments, such as radioiodine ablation, were pursued as
clinically indicated. Histopathologic diagnoses of thyroid cancer were estab-
lished according to theWHOcriteria.27BRAFV600Emutation in primary PTC
was examined and documented as previously described.23,25 BRAF
V600Emutation status was determined after surgical andmedical treatments
in all patients and did not affect decision making regarding treatments.
Statistical Analyses
Spearman correlation coefﬁcient was calculated to evaluate the associ-
ation between patient age and PTC-speciﬁcmortality. Variance inﬂation factor
to test multicollinearity was calculated for each clinicopathologic characteristic
in the Cox hazards regression model; all variance inﬂation factors were low
(ie, , 1.58), ensuring that multicollinearity was not a problem in the re-
gression models. Multivariate Cox proportional hazards regression models
with restricted cubic splines (RCS) and adaptive splines were used to
demonstrate the continuous relationship between patient age and PTC-
speciﬁc mortality.19 Hazard ratios (HRs) were natural logarithm-transformed
and adjusted for multivariate clinicopathologic characteristics. The RCSmodel
(knot number, 3) was used to estimate the HR and 95% CI of different ages
compared with age 45 years. Comparing the statistical ﬁtness of different
Table 1. Clinicopathologic Characteristics of Patients With PTC
Characteristic All Patients (N = 2,638)*
Patients With Wild-Type
BRAF (n = 1,524)
Patients With BRAF V600E
(n = 1,094)
Median age at diagnosis, years (IQR) 46 (35-58) 44 (34-56) 48 (36-59)
Female sex, No. (%) 2,015 (76.4) 1,175 (77.1) 822 (75.1)
Median tumor size, cm (IQR) 1.5 (1.0-2.5) 1.5 (0.9-2.5) 1.6 (1.1-2.5)
Subtype, No. (%)
CPTC 1,893 (71.8) 996 (65.4) 883 (80.7)
FVPTC 525 (19.9) 413 (27.1) 107 (9.8)
TCPTC 100 (3.8) 26 (1.7) 74 (6.8)
Other 120 (4.5) 89 (5.8) 30 (2.7)
AJCC stage, No./total No. (%)
I 1,819/2,618 (69.5) 1,138/1,512 (75.3) 667/1,086 (61.4)
II 185/2,618 (7.1) 118/1,512 (7.8) 66/1,086 (6.1)
III 414/2,618 (15.8) 174/1,512 (11.5) 235/1,086 (21.6)
IV 200/2,618 (7.6) 82/1,512 (5.4) 118/1,086 (10.9)
Extrathyroidal extension, No./total No. (%) 668/2,634 (25.4) 274/1,522 (18.0) 387/1,092 (35.4)
Lymph node metastasis, No./total No. (%) 896/2,613 (34.3) 449/1,505 (29.8) 437/1,088 (40.2)
Vascular invasion, No./total No. (%) 158/1,051 (15.0) 83/693 (12.0) 75/358 (20.9)
Distant metastasis, No./total No. (%) 118/2,615 (4.5) 64/1,508 (4.2) 54/1,087 (5.0)
131I treatment, No./total No. (%) 1,984/2,559 (77.5) 1,067/1,481 (72.0) 897/1,058 (84.8)
Median administered activities of 131I, mCi (IQR) 100 (30-100) 78 (0-100) 100 (50-104)
Recurrence, No. (%) 423 (16.0) 183 (12.0) 239 (21.4)
PTC-speciﬁc mortality, No. (%) 58 (2.2) 16 (1.0) 42 (3.8)
Median follow-up time, months (IQR) 58 (26-107) 62 (28-118) 51 (24-96)
Abbreviations: AJCC, American Joint Committee on Cancer; CPTC, conventional papillary thyroid cancer; FVPTC, follicular-variant papillary thyroid cancer; IQR,
interquartile range; PTC, papillary thyroid cancer; TCPTC, tall-cell papillary thyroid cancer.
*Including 20 patients with no BRAF information.
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number knots showed that the model with 3 knots had the lowest Akaike
information criterion estimate, thus providing the best ﬁt to the data. Adaptive
splines are knot-free and do not rely on knot number. Statistical analyses were
performed using the mgcv28 and rms29 packages in R (version 3.2.4; R
Foundation for Statistical Computing, Vienna, Austria).
RESULTS
Association Between Patient Age and PTC-Specific
Mortality in Patients With BRAF V600E But Not
Wild-Type BRAF
As shown in Figure 1, before the age of 45 years, the mortality
rates (percentages of deaths in the cohort) were low in all of the
patient groups. After the age of 45 years, mortality rates increased
as patient age increased in all patients, andmortality rates increased
evenmore rapidly in patients with BRAFV600Emutation. However,
in striking contrast, there was no increase in mortality overall in
patients with wild-type BRAF (Fig 1A). Accumulated mortality
rates also increased continuously after age 45 years in all patients
and increased even more rapidly and steeply in patients with BRAF
V600E mutation, whereas there was only a marginal increase in ac-
cumulated mortality in patients with wild-type BRAF at age 45 to 64
years (Fig 1B). After age 65 years, the mortality rate began to decrease
(Fig 1A) and the accumulated mortality rate stayed ﬂat (Fig 1B) in
patients with wild-type BRAF, whereas both the mortality rate and the
accumulated mortality rate continuously and sharply increased as
25
20
A B
15
10
5
M
o
rt
al
it
y 
R
at
e 
(%
)
0
Age (years)
< 25 25-34 35-44 45-54 55-64 65-74 ≥ 75
4
3
2
1
A
cc
u
m
u
la
te
d
 M
o
rt
al
it
y 
R
at
e 
(%
)
0
Age (years)
< 25
All 0.00% 0.23% 0.34% 1.74% 3.85% 5.60% 13.33% All 0.00% 0.04% 0.11% 0.49% 1.21% 1.74% 2.20%
0.00% 0.56% 0.00% 2.90% 4.55% 9.68% 23.53%BRAF V600E 0.00% 0.09% 0.09% 0.73% 1.65% 2.74% 3.84%BRAF V600E
0.00% 0.00% 0.54% 0.91% 3.35% 1.64% 0.00%BRAF wild-type 0.00% 0.00% 0.13% 0.33% 0.92% 1.05% 1.05%BRAF wild-type
< 35 < 45 < 55 < 65 < 75 All
C D
25
20
15
10
5M
o
rt
al
it
y 
R
at
e 
(%
)
0
Age (years)
< 25 25-34 35-44 45-54 55-64 65-74 ≥ 75
4
5
3
2
1
A
cc
u
m
u
la
te
d
 M
o
rt
al
it
y 
R
at
e 
(%
)
0
Age (years)
< 25
0.00% 0.32% 0.00% 1.69% 3.80% 6.74% 11.76%
0.00% 0.64% 0.00% 3.06% 4.94% 12.12% 21.05%
0.00% 0.00% 0.00% 0.46% 2.82% 0.00% 0.00%
All
BRAF V600E
BRAF wild-type
0.00% 0.05% 0.05% 0.42% 1.11% 1.74% 2.17%
0.00% 0.11% 0.11% 0.79% 1.70% 3.06% 3.96%
0.00% 0.00% 0.00% 0.10% 0.60% 0.60% 0.60%
All
BRAF V600E
BRAF wild-type
< 35 < 45 < 55 < 65 < 75 All
Fig 1. Relationship between patient age and papillary thyroid cancer (PTC)–speciﬁc mortality in all patients, patients with BRAF V600E mutation, and patients with
wild-type BRAF. (A) Mortality rates and (B) accumulated mortality rates by patient age in all patients with PTC. (C) Mortality rates and (D) accumulated mortality rates of
patients with conventional PTC.
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patient age increased in patients with BRAF V600E (Figs 1A and
1B). Spearman correlation analysis showed a strongly positive
correlation between patient age and mortality rate in BRAF
V600E patients (P = .002, r = 0.94), but the correlation was not
signiﬁcant in wild-type BRAF patients (P = .36, r = 0.41).
Virtually identical results were obtained when only patients with
CPTC were analyzed (Figs 1C and 1D). Spearman correlation
analysis also showed a strongly positive correlation between patient
age and mortality in patients with CPTC harboring BRAF V600E
(P, .002, r = 0.94), but not in patients with CPTC harboring wild-
type BRAF (P = .70, r = 0.18). These results suggest that the as-
sociation between patient age and PTC-speciﬁc mortality depends
on BRAF V600E status.
Rapidly Progressive Decline in Kaplan-Meier Survival
Curve With Increasing Age in Patients With BRAF
V600E But Not Wild-Type BRAF
In the analysis of all patients, Kaplan-Meier survival curves
progressively declined as patient age increased, particularly after age
45 years; decline was sharpest in patients$ 75 years old (Fig 2A). An
even more rapidly progressive decline in survival curve was seen
in patients with BRAF V600E as patient age increased (Fig 2B). In
striking contrast, there was no progressive decline in survival curve
in patients with wild-type BRAF as patient age increased (Fig 2C).
Speciﬁcally, in patients with BRAFV600E, survival curves in patients
younger than 45 years old were largely ﬂat, and only one death
occurred in the 25- to 34-year age group at a follow-up time of
300 months. Starting at age 45 years, the older the patients were, the
more rapidly the survival curve declined and the most rapid decline
occurred in patients $ 75 years old (Fig 2B). Similar results were
observed when only patients with CPTC were analyzed (Fig 3).
These results demonstrate a BRAF V600E–dependent association
between decreasing PTC-speciﬁc patient survival and increasing
patient age.
Independent Linear Association Between Mortality Risk
and Increasing Age in Patients With BRAF V600E But
Not Wild-Type BRAF
We used multivariate Cox proportional hazards regression
models with RCS to further analyze the relationship between
patient age and PTC-speciﬁc mortality with adjustment for the
classic clinicopathologic characteristics of patient sex, tumor
size, extrathyroidal extension, lymph node metastasis, distant
metastasis, and administered activities of radioactive iodine (mCi),
which are factors known to affect clinical outcomes of patients with
PTC, as well as study center (Fig 4). To be comparable, for all RCS
plots, patient age of 45 years, which was close to the median age of
our cohort, was chosen as the reference for HR calculation. In all
patients combined, RCS analysis demonstrated a nearly linear
association between patient age and PTC-speciﬁc mortality risk,
with the adjusted log HR continuously increasing as patient age
increased (Fig 4A). In patients with BRAF V600E, an even stronger
and steeper linear relationship between patient age and adjusted log
HRof PTC-speciﬁcmortality risk was observed (Fig 4B). In contrast,
in patients with wild-type BRAF, no signiﬁcant relationship was
observed between patient age andmortality risk; themortality risk at
various age segments generally did not show signiﬁcant difference,
and the line stayed ﬂat as the patient age increased, even after age 75
years (Fig 4C). The increasing line before age 45 years is a result of
the large variance from the low mortality rate in this young patient
age range, which displayed insigniﬁcant HRs in reference to patient
age of 45 years.
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Fig 2. Kaplan-Meier analysis of disease-speciﬁc survival curves of patients with papillary thyroid cancer (PTC) in various patient age groups: (A) all patients; (B) patients
with BRAF V600E mutation; and (C) patients with wild-type BRAF.
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The adjusted speciﬁc HRs at different age points are presented
in Fig 4D. HRs increased from age 20 to 80 years in the analysis of
all patients. An even stronger upward trend in HRs was observed
from age 20 to 80 years in patients with BRAF V600E, particularly
after age 50 years. In contrast, in patients with wild-type BRAF, the
HR was marginally signiﬁcant only at age 50 years and was in-
signiﬁcant at all other age points (Fig 4D). Similar results were
observed when only patients with CPTC were analyzed using RCS
(Appendix Fig A1, online only).
We also used adaptive smoother spline (Fig 5), used previously
by Adam et al,19 to analyze the relationship between patient age and
PTC-speciﬁc mortality and obtained similar results. Speciﬁcally, in
analyses of all patients, a near-linear association between patient
age and mortality risk was seen (Fig 5A). An even steeper linear
association between patient age and mortality risk was seen in
patients with BRAF V600E (Fig 5B). In contrast, no signiﬁcant
association between patient age and mortality risk was seen in
patients with wild-type BRAF (Fig 5C). Similar results were ob-
tained when only patients with CPTC were analyzed using the
adaptive smoother spline (Appendix Fig A2, online only).
DISCUSSION
Since Crile and Hazard described the association between ad-
vanced patient age and aggressiveness of thyroid cancer almost 65
years ago,7 numerous studies have conﬁrmed this phenomenon.
Today, patient age is a well-established mortality risk factor in the
prognostication of thyroid cancer; various clinical guidelines and
risk assessment models uniformly incorporate patient age as
a major risk factor in the management of thyroid cancer.8-10,30,31
To further support the prognostic importance of patient age,
a linear relationship between patient age and PTC-speciﬁc mortality
was recently demonstrated, suggesting a continuous adverse impact
on PTC prognosis as patient age increases.19 For thyroid cancer, the
previous and recent editions of the AJCC staging system heavily
emphasize the general risk of patient age.13,14 Thus, patient age has
profoundly inﬂuenced the risk stratiﬁcation and management of
PTC. However, it remains to be determined whether patient age is
a major risk factor for all patients with PTC.
This study explored the effect of BRAFV600E on age-associated
mortality risk in patients with PTC. We reproduced the ﬁndings of
Adam et al19 by demonstrating a similar linear association between
patient age and PTC-speciﬁc mortality in the analysis of all patients
combined. However, this linear relationship was even steeper in
patients with BRAF V600E, particularly in patients older than age 45
years. In contrast, this association was lost in patients with wild-type
BRAF, in whom the PTC-speciﬁc mortality risk remained ﬂat with
increasing patient age, even after age 45 years. Thus, the long-
observed age-associated mortality risk in PTC is BRAF V600E
dependent; patient age itself, in the absence of BRAF V600E, is
not a signiﬁcant risk factor. These ﬁndings challenge the conventional
belief that older patient age is uniformly amortality risk factor in PTC
and question its universal application in risk stratiﬁcation of PTC.
Instead, the utility of patient age as a prognostic risk factor depends
on BRAF V600E status. Speciﬁcally, in patients with BRAF V600E,
age has a strong and continuous adverse effect on the prognosis of
patients with PTC throughout the entire age spectrum examined, and
in fact, the effect intensiﬁes as patient age increases. Thus, in patients
with BRAF V600E mutation, age is an important factor in risk
stratiﬁcation and management of PTC as conventionally applied.
In contrast, in patients with wild-type BRAF, age is not a risk
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Fig 3. Kaplan-Meier analysis of disease-speciﬁc survival curves of patients with conventional papillary thyroid cancer (CPTC) in various patient age groups: (A) all patients;
(B) patients with BRAF V600E; and (C) patients with wild-type BRAF.
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factor for poor prognosis; in these patients, both younger and
older patients have a similar PTC-speciﬁc mortality risk and may
be managed similarly. This new concept will likely have a major
impact on the clinical management of PTC because the preva-
lence of BRAF V600E mutation in PTC is, on average, 45%.20
Thus, the majority of patients with PTC have wild-type BRAF,
and in these patients, conventional use of patient age as a major
risk factor is not valid. As such, many older patients will be able to
avoid more aggressive treatment that would otherwise be ad-
ministered as a result of the conventional concept of older patient
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Fig 4. Multivariate Cox proportional hazards regression analysis of papillary thyroid cancer (PTC)–speciﬁc mortality risk with restricted cubic splines (RCS). Continuous linear
association between patient age and PTC-speciﬁc mortality was observed (A) in the analysis of all patients and (B) even more signiﬁcantly in patients with BRAF V600E, but
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lymph nodemetastasis, distantmetastases, administered activities of radioactive iodine, and study center. The RCS plots were performedwith the age of 45 years as the reference
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Age (years)
20 6040 80
All PTC patients
−20
−15
−10
−5
0
5
Ad
ju
st
ed
 L
og
 H
az
ar
d 
Ra
tio
A
Age (years)
20 6040 80
PTC patients with
BRAF V600E
−20
−15
−10
−5
0
5
Ad
ju
st
ed
 L
og
 H
az
ar
d 
Ra
tio
B
Age (years)
20 6040 80
PTC patients with
wild-type BRAF
−20
−15
−10
−5
0
5
Ad
ju
st
ed
 L
og
 H
az
ar
d 
Ra
tio
C
Fig 5. Multivariate Cox proportional hazards regression analysis of papillary thyroid cancer (PTC)–speciﬁc mortality risk with adaptive smoother splines in (A) all patients with
PTC, (B) patients with BRAF V600E mutation, and (C) patients with wild-type BRAF. The blue line represents the ﬁtted line of the association between patient age and the
estimated hazard ratio of mortality after adjustment; the shaded region represents the 95% CI. The models were adjusted for the following clinicopathologic characteristics:
patient sex, tumor size, extrathyroidal extension, lymph node metastasis, distant metastases, administered activities of radioactive iodine, and study center.
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age being a general high-risk factor. Our study calls for a BRAF
genotype–based modiﬁcation of the conventionally used risk
assessment systems,8-10,30,31 as well as the recently developed
quantitative risk assessment nomogram,32 which all incorporate
patient age as a general risk factor for thyroid cancer. In addition,
given this differentiating role of BRAF V600E status in patient
age-related mortality risk of PTC, use of the conventional cutoff
age of 45 years13 or the new cutoff age of 55 years14 in the risk
stratiﬁcation of PTC is inaccurate. Our study addressed the role of
BRAF V600E mutation in PTC-speciﬁc mortality risk related to
patient age at diagnosis. It would be interesting for future studies
to investigate the role of the mutation in the dynamic effect, if any,
of patient age on the prognosis of PTC as the age of the same
patient increases after the diagnosis.
The large multicenter cohort of patients is a major strength of
this study and is one of the largest cohorts of patients in BRAF
mutation–related studies in thyroid cancer. The multicenter nature,
however, is inherently associated with the potential limitation of data
heterogeneity, as seen in population data such as the SEER data.19
Nevertheless, our study only looked at the single outcome parameter
of PTC-speciﬁc patient death, which has a universally straightfor-
ward deﬁnition, and the binary data of BRAFmutation–positive and
–negative status from each participating center were similarly in-
cluded in the analysis. The participating centers are well-known
thyroid cancer centers that actively follow contemporary standard
practice guidelines in themanagement of thyroid cancer, minimizing
the heterogeneity in themanagement of thyroid cancer. The fact that
the overall analysis of all patients in the current study fully repro-
duced the ﬁndings of the linear effect of patient age on PTC-speciﬁc
mortality in the study by Adam et al19 is consistent with the good
generalizability of the current study. Another limitation is that TERT
promoter mutation, which is also a prognostic genetic event in PTC,
was not included in this study. However, TERT promoter mutations
are relatively uncommon and mostly coexist with BRAFmutation in
PTC.33,34 Moreover, TERT promoter mutation alone has limited or
virtually no effect on PTC-speciﬁc mortality.35,36 Therefore, lack of
information on TERT promoter mutation should not affect the
clinical implications of this study on the use of BRAFV600E status in
differentiating patient age–related mortality risk in PTC.
Themolecular mechanism for the BRAFmutation–dependent
effect of patient age on the prognosis of PTC remains to be de-
ﬁned. It is possible that certain age-associated genes, such as im-
mune response–related genes,37 may cooperate with mutant BRAF
in conferring poor prognosis because BRAF V600E was shown to
be linked to abnormal immune responses in human cancers, in-
cluding PTC.38-40 Another potential and more likely mechanism is
the coexistence of BRAF V600E and TERT promoter mutations,
which are synergistically associated with poor clinical outcomes in
PTC, including disease recurrence and patient mortality.35,36 Both
BRAF V600E20-22 and TERT promoter mutations34 occur in PTC
more commonly in older patients. The present results are also
consistent with a previous ﬁnding that BRAF V600E and older
patient age had a synergistic effect on PTC-related mortality.25
In summary, in contrast to the long-held practice of treating
patient age as a general risk factor for PTC, this large multicenter
study demonstrates that age is a strong and continuous mortality
risk factor only in patients with BRAF V600E mutation, and not in
the more commonly seen patients with wild-type BRAF. These
results call for differentiation between patients with wild-type
BRAF and BRAF V600E when applying age to risk stratiﬁcation
and management of patients with PTC. This study has broad
clinical implications.
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Fig A1. Multivariate Cox proportional hazards regression analysis ofmortality riskwith restricted cubic splines (RCS) in patientswith conventional papillary thyroid cancer (CPTC).
(A) A continuous and nearly linear association between patient age and CPTC-speciﬁc mortality was observed in all patients. (B) The association was linear and even steeper in
patients with BRAF V600E mutation. (C) A linear association was not seen in patients with wild-type BRAF. The blue line represents the ﬁtted line of the association
between patient age and the estimated hazard ratio (HR) of mortality risk after adjustment; the shaded region represents the 95% CI. The models were adjusted for the
following clinicopathologic characteristics: patient sex, tumor size, extrathyroidal extension, lymph nodemetastasis, distant metastases, administered activities of radioactive
iodine, and study center. The RCS plots were performed with the age of 45 years as the reference for HR calculation. (D) Speciﬁc HRs and 95% CIs were calculated for the
indicated age points. (*) Signiﬁcantly different HRs in reference to patient age of 45 years. Because of the small number of deaths in patients younger than age 45 years, there
were large variations in log HRs in patients with CPTC harboring only wild-type BRAF in the young age ranges. Consequently, different y-axis scales are used for log HR for
panels A, B, and C.
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Table A1. Demographic Characteristics of Patients by Medical Center and
Country
Center and Country
No. of
Patients
Median
(IQR) Age at
Diagnosis
(years)
No. of Male
Patients (%)
By medical center
Johns Hopkins Hospital (United
States)
1,051 46 (36-57) 287 (27.3)
University of Pisa (Italy) 189 38 (28-51) 47 (24.9)
University of Perugia (Italy) 117 49 (37-59) 32 (27.4)
University of Milan (Italy) 265 45 (36-58) 63 (23.8)
Maria Sklodowska-Curie Memorial
Cancer Centre and Institute of
Oncology (Poland)
253 47 (35-59) 30 (11.9)
Grifﬁth University (Australia) 76 40 (34-56) 20 (26.3)
University of Padua (Italy) 135 48 (39-57) 32 (23.7)
University of Pittsburgh (United
States)
169 52 (38-63) 42 (24.9)
Hospital La Paz Health Research
Institute, Madrid (Spain)
66 42 (32-54) 11 (16.7)
University of Sydney (Australia) 95 44 (34-59) 20 (21.1)
Institute of Endocrinology, Prague
(Czech Republic)
222 47 (31-60) 39 (17.6)
By country
United States 1,220 47 (37-58) 329 (27.0)
Italy 706 45 (34-56) 174 (24.6)
Poland 253 47 (35-59) 30 (11.9)
Australia 171 43 (34-57) 40 (23.4)
Spain 66 42 (32-54) 11 (16.7)
Czech Republic 222 47 (31-60) 39 (17.6)
Overall 2,638 46 (35-58) 623 (23.6)
Abbreviation: IQR, interquartile range.
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Fig A2. Multivariate Cox proportional hazards regression analysis of conventional papillary thyroid cancer (CPTC)–speciﬁc mortality risk with adaptive smoother splines:
(A) all CPTC patients; (B) CPTC patients with BRAF V600E mutation; and (C) CPTC patients with wild-type BRAF. The blue line represents the ﬁtted line of the association
between patient age and the estimated hazard ratio (HR) of mortality risk after adjustment; the shaded region represents the 95% CI. The models were adjusted for the
following clinicopathologic characteristics: patient sex, tumor size, extrathyroidal extension, lymph node metastasis, distant metastases, administered activities of ra-
dioactive iodine, and study center. Because of the small number of deaths in patients younger than age 45 years, there were large variations in log HRs in patients with
CPTC harboring only wild-type BRAF in the young age ranges. Consequently, different y-axis scales are used for log HR for panels A, B, and C.
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